Breathe Well Live Well
The Augusta Chronicle |
University offers new severe asthma treatment
The Augusta Chronicle Ball, 66, of Augusta was the first patient at University Hospital, and likely the first in Augusta, to get bronchial thermoplasty to treat his severe persistent asthma. The procedure involved threading a catheter through a bronchoscope into the lungs … |
View full post on asthma – Google News
Chicago Tribune |
Insurers balk at asthma treatment that doesn't involve drugs
Chicago Tribune "Most asthma is easy to control with great drugs and inhalers, but there is a group of people that despite all that, their asthma is still a huge problem for them," Hogarth said. "So what do you do for that group? And that's where thermoplasty comes in . |
View full post on asthma – Google News
|
Establishing a 'Yellow Zone' for Asthma Treatment
HCPLive While some exacerbations of asthma require trips to the doctor or emergency room, work is being done to help patients control their condition better in the comfort of their own home. Chitra Dinakar, MD, from Children's Mercy Hospital discussed these … |
View full post on asthma – Google News
Medical Xpress |
Investigating mutations of a crucial gene might assist treatment and …
Medical Xpress Allergic asthma affects the lives of millions but new research may help to prevent or suppress an allergic response. Credit: Giorez/iStock/Thinkstock. Mutations in a specific gene are linked with human susceptibility to allergic asthma according to new … |
View full post on asthma – Google News
Effect of Common Comparators in Indirect Comparison Analysis of the Effectiveness of Different Inhaled Corticosteroids in the Treatment of Asthma.
PLoS One. 2015;10(3):e0120836
Authors: Kunitomi T, Hashiguchi M, Mochizuki M
Abstract
PURPOSE: Indirect comparison (IC) and direct comparison (DC) of four inhaled corticosteroid (CS) treatments for asthma were conducted, and the factors that may influence the results of IC were investigated. Among those factors, we focused on the effect of common comparator selection in the treatment of asthma, where little control group bias or placebo effect is expected.
METHOD: IC and DC were conducted using the change from baseline in forced expiratory volume in 1 s (FEV1(L)) as an outcome parameter. Differences between inhaled CS were evaluated to compare the results of IC and DC. As a common comparator for IC, placebo (PLB) or mometasone (MOM) was selected. Whether the results of IC are affected by the selection of a common comparator and whether the results of IC and DC are consistent were examined.
RESULTS: 23 articles were identified by a literature search. Our results showed that ICs yielded results similar to DCs in the change from baseline of FEV1(L). No statistically significant difference was observed in inconsistency analysis between ICs and DCs. It was clinically and statistically confirmed that ICs with PLB and those with MOM did not differ in terms of the results of FEV1(L) analysis in this dataset.
CONCLUSION: This study demonstrated that ICs among inhaled CS can deliver results consistent with those of DCs when using the change from baseline in FEV1(L) as an outcome parameter in asthma patients. It was also shown that using an active comparator has similar results if there is no effect of control group bias. It should be emphasized that the investigation of control group bias is a key factor in conducting relevant ICs so that an appropriate common comparator can be selected.
PMID: 25793900 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Uncover California |
FDA Panel Recommends Asthma Treatment Approval for Adults Only
Pharmacy Times (registration) "We recognize the advisory committee's thoroughness in reviewing the data related to Breo Ellipta for asthma,” said Darrell Baker, senior vice president and head of GSK's Global Respiratory Franchise, in a press release. “We will continue to work … GSK And Theravance: Implications Of The Advisory Panel Decision Breo Ellipta receives Mixed Views from FDA Panel |
View full post on asthma – Google News
|
Report: U.S. Market for Asthma Treatment to See Modest Growth
Pharmaceutical Processing A new report expects the U.S. market for treatment asthma to grow from $11.7 billion in 2013 to $14 billion by 2020. The analysis by New York-based GBI Research predicted the recent expiration of patents for several of the top current therapeutics … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: omalizumab; Biological: Rhinovirus (strain 16)
Sponsors: University of Virginia; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting – verified March 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Frontline Desk |
New Glaxo asthma treatment reviewed by FDA
Frontline Desk The bureau employees same on Tuesday there have been no asthma-related deaths in Breo Ellipta studies, it reviewed which information on asthma-related hospitalizations weren't determined uniformly within the twenty three studies that Glaxo conducted. |
View full post on asthma – Google News
Condition: Patient Satisfaction
Intervention: Drug: Budesonide, Formoterol Fumarate Dihydrate
Sponsor: Teva Pharma GmbH
Active, not recruiting – verified March 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days